CLINICAL SIGNIFICANCE OF HEMOSTASIS AND LABORATORY-IMMUNOLOGICAL INDICATOR DYNAMICS IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS WHO HAD COVID-19
DOI:
https://doi.org/10.37547/Keywords:
rheumatoid arthritis, COVID-19, hemostasis, D-dimer, fibrinogen, platelets, tocilizumab, thromboinflammatory activityAbstract
Rheumatoid arthritis (RA) is a chronic, immune-mediated inflammatory disease in which sustained systemic inflammatory activity is frequently accompanied by disturbances of the hemostatic system and a consequently elevated risk of thromboembolic complications. The COVID-19 pandemic introduced an additional pathogenetic dimension to this problem: by virtue of its pronounced prothrombotic and proinflammatory potential, SARS-CoV-2 infection is capable of aggravating the pre-existing thromboinflammatory milieu characteristic of RA, thereby complicating both the clinical course of the disease and the choice of therapeutic strategy. Against this background, a systematic evaluation of the dynamics of hemostatic and laboratory-immunological parameters over the course of treatment in RA patients who have recovered from COVID-19, together with a comparative analysis of the influence exerted by different therapeutic regimens on these parameters, acquires considerable practical and clinical significance.
Downloads
References
1.Abduazizova N.Kh., Sagatova D.R., Sharapov Z.A., et al. COVID-19 in cases of rheumatoid arthritis. Infektsiya, immunitet i farmakologiya. 2022;(5):8–13.
2.Sharapov Z.A. Modern views on the etiology and pathogenesis of rheumatoid arthritis. Eurasian Journal of Medical and Natural Sciences. 2022;2(2):103–107.
3.Landewe R.B.M., Machado P.M., Kroon F., et al. EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. Ann Rheum Dis. 2020;79(7):851–858.
4.Alunno A., Najm A., Machado P.M., et al. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Ann Rheum Dis. 2022;81(1):34–40. doi:10.1136/annrheumdis-2021-221366.
5.Jin L., Gan J., Li X., et al. Rheumatoid arthritis and COVID-19 outcomes: a systematic review and meta-analysis. BMC Rheumatology. 2024;8(1):61. doi:10.1186/s41927-024-00431-5.
6.Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7(6):e438–e440. doi:10.1016/S2352-3026(20)30145-9.
7.Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000.
8.Zinellu A., et al. A systematic review and meta-analysis of the association between the D-dimer and rheumatic diseases. Immun Inflamm Dis. 2024;12(7):e1349. doi:10.1002/iid3.1349.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under this license:
- Share: Copy and redistribute the material in any medium or format
- Adapt: Remix, transform, and build upon the material for any purpose, including commercially
Attribution required: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
License URL: https://creativecommons.org/licenses/by/4.0/
Authors retain copyright of their work while granting the journal first publication rights.
